Isarna Therapeutics Attracts New Investment For Next-Generation Antisense Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Following a Phase III disappointment with its lead anticancer candidate, Germany’s Isarna Therapeutics has garnered new funding to advance its preclinical pipeline of oligonucleotides targeting TGF-beta.